KRAS and neoplasm: This analysis revealed that in 2 out of the 3 PDX models, KRAS signalling was significantly elevated in metastatic PDX tissue relative to primary tumor (S10–S12 Tables), consistent with the mutational activation observed in the exome-sequence analysis described here.